Dronedarone in high-risk permanent atrial fibrillation

Stuart J Connolly, A John Camm, Jonathan L Halperin, Campbell Joyner, Marco Alings, John Amerena, Dan Atar, Álvaro Avezum, Per Blomström, Martin Borggrefe, Andrzej Budaj, Shih-Ann Chen, Chi Keong Ching, Patrick Commerford, Antonio Dans, Jean-Marc Davy, Etienne Delacrétaz, Giuseppe Di Pasquale, Rafael Diaz, Paul DorianGreg Flaker, Sergey Golitsyn, Antonio Gonzalez-Hermosillo, Christopher B Granger, Hein Heidbüchel, Josef Kautzner, June Soo Kim, Fernando Lanas, Basil S Lewis, Jose L Merino, Carlos Morillo, Jan Murin, Calambur Narasimhan, Ernesto Paolasso, Alexander Parkhomenko, Nicholas S Peters, Kui-Hian Sim, Martin K Stiles, Supachai Tanomsup, Lauri Toivonen, János Tomcsányi, Christian Torp-Pedersen, Hung-Fat Tse, Panos Vardas, Dragos Vinereanu, Denis Xavier, Wei Jun Zhu, Jun-Ren Zhu, Lydie Baret-Cormel, PALLAS Investigators, Jørgen Lykke Jeppesen

552 Citationer (Scopus)

Abstract

Dronedarone restores sinus rhythm and reduces hospitalization or death in intermittent atrial fibrillation. It also lowers heart rate and blood pressure and has antiadrenergic and potential ventricular antiarrhythmic effects. We hypothesized that dronedarone would reduce major vascular events in high-risk permanent atrial fibrillation.
OriginalsprogEngelsk
TidsskriftNew England Journal of Medicine
Vol/bind365
Udgave nummer24
Sider (fra-til)2268-76
Antal sider9
ISSN0028-4793
DOI
StatusUdgivet - 2011

Fingeraftryk

Dyk ned i forskningsemnerne om 'Dronedarone in high-risk permanent atrial fibrillation'. Sammen danner de et unikt fingeraftryk.

Citationsformater